高级检索
当前位置: 首页 > 详情页

Orbital Oncocytic Carcinoma: A Comprehensive Case Series and Literature Review

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Beijing Institute of Ophthalmology, Beijing Tongren Eye Center. [2]Pathology Department, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
出处:
ISSN:

摘要:
This case series and literature review evaluated the baseline variables, clinical symptoms, pathological characteristics, and prognosis of patients with orbital oncocytic carcinoma.This retrospective case series collected the medical histories and other related data from 13 patients pathologically diagnosed with oncocytic carcinoma.The average age of patients with orbital oncocytic carcinoma was 64.8 years, with a significantly higher rate of males than females. Furthermore, unilateral disease was more common than bilateral disease. All patients had surrounding tissue invasion, most commonly to extraocular muscles (69.2%) and bones (53.8%). The clinical manifestations were proptosis (30.8%), swelling of the lesion area (23.1%), vision loss (23.1%), diplopia (23.1%), periocular mass (23.1%), tears (15.4%), eye pain (7.7%), ptosis (7.7%), and visual field loss (7.7%). Microscopic examination revealed many large eosinophilic cells. There were obvious nuclei and abundant mitotic figures. The cancer cells expressed cytokeratin, but not P63 or S-100. The follow-up duration was 2-53 months, and the metastasis rate was 16.7%. The patients exhibited a good prognosis. The main treatment methods included surgical resection, surgery combined with radiotherapy, and the enucleation of ocular contents.Orbital oncocytic carcinoma has the immunohistochemical characteristics of eosinophilic tumor cells, with expression of cytokeratin but not P63 or S-100. The prognosis is favorable. Surgical resection, surgery combined with radiotherapy, and enucleation of intraocular material are effective treatment options. Nevertheless, long-term follow-up and close observation for metastases are required.Copyright © 2024 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 4 区 医学
小类 | 4 区 眼科学 4 区 外科
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 眼科学 4 区 外科
JCR分区:
出版当年[2022]版:
Q3 OPHTHALMOLOGY Q3 SURGERY
最新[2023]版:
Q3 SURGERY Q3 OPHTHALMOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Beijing Institute of Ophthalmology, Beijing Tongren Eye Center.
共同第一作者:
通讯作者:
通讯机构: [1]Beijing Institute of Ophthalmology, Beijing Tongren Eye Center. [*1]Department of Ophthalmic Oncology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)